Yang Liu, PhD
Assistant Professor of PathologyCards
Appointments
Contact Info
About
Copy Link
Titles
Assistant Professor of Pathology
Biography
Yang Liu, PhD, was appointed Assistant Professor in the Department of Pathology effective August 1, 2022. Dr. Liu received his PhD degree from the University of California Riverside, working in quite a few different fields, including engineering, chemistry, toxicology, and computer science. He has been a Postdoctoral Research Associate at Yale since 2018 working with Dr. Rong Fan in the Department of Biomedical Engineering at Yale. During the Postdoc training, he developed a high spatial resolution multi-omics sequencing technique, named DBiT-seq, which can achieve near single-cell spatial resolution (10 µm) sequencing of RNA and protein on the same tissue section. He also developed Spatial-CITE-seq (High plex spatial epitome sequencing) and DBiT-seq FFPE technology (spatial transcriptome and epitome of banked FFPE samples). Dr. Liu received the SITC-SU2C Convergence Scholar Awards in 2019 and NIH Hubmap Jumpstart award. His Lab in Yale Pathology will focus on development of spatial based omics techniques (Transcriptome, proteome, epigenome, etc..) and the application of spatial omics techniques to study tumor microenvironments, neurological disease, heart and vascular disease, development and microbiome.
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of California, Riverside, Environmental Toxicology (2017)
- MS
- University of California, Riverside, Computer Science (2017)
- MS
- Chinese Academy of Science, Analytical Chemistry (2011)
- BS
- Huazhong University of Science & Technology, Computer Science (2008)
- BE
- Huazhong University of Science & Technology, Environmental Engineering (2008)
Research
Copy Link
Overview
Yang Liu, PhD, was appointed Assistant Professor in the Department of Pathology effective August 1, 2022. Dr. Yang Liu received his PhD degree from the University of California Riverside, working in quite a few different fields, including engineering, chemistry, toxicology, and computer science. He has been a Postdoctoral Research Associate at Yale since 2018 working with Dr. Rong Fan in the Department of Biomedical Engineering at Yale. During the Postdoc training, he developed a high spatial resolution multi-omics sequencing technique, named DBiT-seq, which can achieve near single-cell spatial resolution (10 µm) sequencing of RNA and protein on the same tissue section. He also developed Spatial-CITE-seq (High plex spatial epitome sequencing) and DBiT-seq FFPE technology (spatial transcriptome and epitome of banked FFPE samples). Dr. Liu received the SITC-SU2C Convergence Scholar Awards in 2019 and NIH Hubmap Jumpstart award. His Lab in Yale Pathology will focus on development of spatial based omics techniques (Transcriptome, proteome, epigenome, etc..) and the application of spatial omics techniques to study tumor microenvironments, neurological disease, heart and vascular disease, development and microbiome.
ORCID
0000-0002-9442-700X- View Lab Website
Yang Liu Lab
Research at a Glance
Yale Co-Authors
Publications Timeline
David A. Hafler, MD, FANA
Joseph Craft, MD
Mina Xu, MD
Publications
2025
pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies
Zhang M, Li J, Yan K, Zhou H, Mei S, Wang B, Li D, Du X, Liu M, Zhang P, Fields J, Ye L, Zheng P, Liu Y, Lenardo M, Zhang Y. pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2422731122. PMID: 39964714, PMCID: PMC11874271, DOI: 10.1073/pnas.2422731122.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAnti-CTLA-4 AbImmunotherapy-related adverse eventsBinding to CTLA-4CTLA-4Antitumor activityAnti-CTLA-4 antibodyAnti-CTLA-4Effective cancer immunotherapyCancer immunotherapyTumor regressionTumoricidal efficacyAdverse eventsTherapeutic indexCancer therapySide effectsEarly endosomesLate endosomesNo enhancementConfocal microscopyIntracellular dissociationCancerAntitumorEfficacyLysosomal degradationIpilimumab
2024
IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10.
Liu J, Jabbari A, Lin C, Akkanapally V, Frankel W, Basu S, He K, Zheng P, Liu Y, Bai X. IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10. The Journal Of Immunology 2024, 213: 559-566. PMID: 38975727, PMCID: PMC11333164, DOI: 10.4049/jimmunol.2400056.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsDependovirusDiabetes Mellitus, Type 1DiarrheaForkhead Transcription FactorsGenetic Diseases, X-LinkedGenetic TherapyGerm-Line MutationHumansImmune System DiseasesInterleukin-10Interleukin-27InterleukinsIntestinal DiseasesLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutT-Lymphocytes, RegulatoryConceptsScurfy miceIL-10Gene therapySingle doseGermline mutationsIL-27X-linked (IPEX) syndromeAllogeneic stem cell transplantationInactivating mutationsNaive T cell activationTherapeutic effectRegulatory T cell developmentMutations of FOXP3IL-10 deficiencyRegulatory T cellsStem cell transplantationDownregulation of CD62LT cell activationInduction of IL-10T cell developmentFatal autoimmune diseaseEffector moleculesUpregulation of CD44FOXP3 mutationsIL-10 inductionSiglec-H-/- Plasmacytoid Dendritic Cells Protect Against Acute Liver Injury by Suppressing IFN-γ/Th1 Response and Promoting IL-21+ CD4 T Cells
Ahodantin J, Wu J, Funaki M, Flores J, Wang X, Zheng P, Liu Y, Su L. Siglec-H-/- Plasmacytoid Dendritic Cells Protect Against Acute Liver Injury by Suppressing IFN-γ/Th1 Response and Promoting IL-21+ CD4 T Cells. Cellular And Molecular Gastroenterology And Hepatology 2024, 18: 101367. PMID: 38849082, PMCID: PMC11296256, DOI: 10.1016/j.jcmgh.2024.101367.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsCD4-Positive T-LymphocytesChemical and Drug Induced Liver InjuryConcanavalin ADendritic CellsDisease Models, AnimalInterferon-gammaInterleukin-21InterleukinsLiverMaleMiceMice, Inbred C57BLMice, KnockoutSialic Acid Binding Immunoglobulin-like LectinsSignal TransductionSTAT3 Transcription FactorTh1 CellsConceptsPlasmacytoid dendritic cellsCD4 T cellsAcute liver injuryT cellsKnockout miceSiglec-HLiver inflammationDepletion of plasmacytoid dendritic cellsFunction of plasmacytoid dendritic cellsLiver injuryCD4 T cell activationPlasmacytoid dendritic cell maturationMouse plasmacytoid dendritic cellsTumor necrosis factor-a levelsAbstractText Label="Background &Antigen-presenting cellsT cell activationPhorbol myristate acetate/ionomycinAssociated with attenuationProinflammatory cytokine IL6CD3/CD28 beadsImmunosuppressive phenotypeImmune toleranceDendritic cellsIL-21A phase 2 trial of CD24Fc for prevention of graft-versus-host disease
Magenau J, Jaglowski S, Uberti J, Farag S, Riwes M, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang M, Burns L, Liu Y, Zheng P, Reddy P. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood 2024, 143: 21-31. PMID: 37647633, PMCID: PMC10934299, DOI: 10.1182/blood.2023020250.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute graft-versus-host diseaseGraft-versus-host diseaseHematopoietic stem cell transplantationDose-limiting toxicityMUD hematopoietic stem cell transplantationGVHD-free survivalMultidose regimenMyeloablative conditioningHematologic malignanciesHuman leukocyte antigen-matched unrelated donorsPrevention of graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationCalcineurin inhibitor-based prophylaxisMatched ControlsDose-escalation phaseSingle-dose regimensStem cell transplantationPhase 2 trialSustained drug exposureAssociated with higher ratesDamage-associated molecular patternsExpansion cohortDouble-blindPlacebo-ControlledUnrelated donor
2023
CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Muthana M, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. ELife 2023, 12: rp87281. PMID: 38127423, PMCID: PMC10735222, DOI: 10.7554/elife.87281.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune-related adverse eventsB-cell depletionB cellsT cellsSevere immune-related adverse eventsCTLA-4 antibody ipilimumabRegulatory T cell impairmentEffector memory T cellsAnti-TNF-alpha antibodyAnti-CTLA-4CTLA-4 deficiencyFoxP3+ TregsCD8 T cellsT cell impairmentMemory T cellsRegulatory T cellsPeripheral B cellsB cell lossReduced peripheral B cellsSeveral autoimmune diseasesKnock-In MiceAntibody-drug conjugatesAntibody ipilimumabCombination immunotherapyAutoimmune cytopeniasCTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Muthana M, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. ELife 2023, 12 DOI: 10.7554/elife.87281.3.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsB-cell depletionB cellsT cellsSevere immune-related adverse eventsCTLA-4 antibody ipilimumabRegulatory T cell impairmentEffector memory T cellsAnti-TNF-alpha antibodyCTLA-4 deficiencyAnti-CTLA-4CD8 T cellsMemory T cellsRegulatory T cellsT cell impairmentPeripheral B cellsB cell lossReduced peripheral B cellsSeveral autoimmune diseasesKnock-In MiceAntibody-drug conjugatesAntibody ipilimumabCombination immunotherapyAutoimmune cytopeniasCTLA-4CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
Wu X, Srinivasan P, Basu M, Zimmerman T, Li S, Wang Y, Zheng P, Liu Y, Sandler A. CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma. Frontiers In Immunology 2023, 14: 1176370. PMID: 37346042, PMCID: PMC10279976, DOI: 10.3389/fimmu.2023.1176370.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune-related adverse eventsWhole tumor cell vaccinesTumor cell vaccinesImmune cell infiltrationCell vaccineNeuroblastoma modelCheckpoint inhibitorsAdverse eventsAutoimmune responseCell infiltrationPotential immune-related adverse eventsSystemic administrationImmune related adverse eventsOrgan systemsEffective tumor vaccinesAnti-tumor immunityImmune checkpoint therapyTherapeutic cancer vaccinesWhole tumor cellsCombination of MYCRelated adverse eventsTime of administrationAssociated with inductionTumor vaccinesCheckpoint therapyCD24-Siglec interactions in inflammatory diseases
Liu Y, Zheng P. CD24-Siglec interactions in inflammatory diseases. Frontiers In Immunology 2023, 14: 1174789. PMID: 37228622, PMCID: PMC10203428, DOI: 10.3389/fimmu.2023.1174789.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMultiple cell typesDifferential glycosylationRegulation of inflammatory diseasesBiological significanceSurface CD24Treat graft-vs-host diseaseMetabolic disordersInflammatory diseasesGraft-vs-host diseaseCell typesPhysiological functionsInflammatory response to tissue injurySiglecsResponse to tissue injuryRespiratory distressAutoimmune diseasesCD24Tissue injuryEndogenous ligandClinical translationGlycosylationDiseaseTranslational research
2022
Spatial-CITE-seq: spatially resolved high-plex protein and whole transcriptome co-mapping.
Fan R, Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D. Spatial-CITE-seq: spatially resolved high-plex protein and whole transcriptome co-mapping. Research Square 2022 PMID: 35378748, PMCID: PMC8978952, DOI: 10.21203/rs.3.rs-1499315/v1.Peer-Reviewed Original Research
2021
231 Molecular insights on safety and anti-tumor activity of a non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392
Liu Y, Zhang Y, Du X, Liu M, Fang X, Mu L, Tevetnitsky V, Devenport M, Zheng P. 231 Molecular insights on safety and anti-tumor activity of a non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392. Journal For ImmunoTherapy Of Cancer 2021, 9: a246-a246. DOI: 10.1136/jitc-2021-sitc2021.231.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAnti-CTLA-4 antibodyCell surface CTLA-4Anti-tumor activityEffective cancer immunotherapySurface CTLA-4CTLA-4Regulatory T cellsTreg depletionCancer immunotherapyImmune toleranceT cellsDepletion of regulatory T cellsTumor-infiltrating regulatory T cellsCTLA-4 checkpoint blockadeImmunotherapy-related adverse effectsCTLA-4 checkpointAnti-CTLA-4Clinical testingTumor-infiltrating TregsCTLA-4 moleculesBinding to mouseCellular characterizationCheckpoint blockadeEffective immunotherapyHumanized mice
Academic Achievements & Community Involvement
Copy Link
Honors
honor The HuBMAP Jump Start Award
08/01/2021National AwardNIHDetailsUnited Stateshonor SITC-SU2C Convergence Scholar Awards
09/01/2019National AwardSITC-SU2CDetailsUnited States
News
Copy Link
Get In Touch
Copy Link
Contacts
Locations
Office
Academic Office
300 George Street
New Haven, CT 06511
Lab
Lab
300 George Street
New Haven, CT 06511